Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Study ID
NCT01908426

Study type
Interventional

Study phase
Phase 3

Study status
Active, not recruiting

Trial Acronym

CELESTIAL

Trial Summary

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.

More informations

Trial Starting Date

Sep 26,2013

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

707

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

In order to facilitate the use of our website, we use cookies.